DOMINION RESOURCES INC /VA/ Form FWP June 04, 2013

Free Writing Prospectus Filed Pursuant to Rule 433

To Prospectus dated January 27, 2012

Preliminary Prospectus Supplements, each dated June 3, 2013

Registration Statement File No. 333-179213

DOMINION RESOURCES, INC.

Concurrent Offerings of:

10,000,000 2013 Series A Equity Units

(Initially Consisting of 10,000,000 2013 Series A Corporate Units)

(the Series A Equity Units Offering)

and

10,000,000 2013 Series B Equity Units

(Initially Consisting of 10,000,000 2013 Series B Corporate Units)

(the Series B Equity Units Offering and, together with the Series A Equity Units Offering, the Offerings)

Pricing Term Sheet dated

June 3, 2013

The information in this pricing term sheet relates to the Offerings and should be read together with (i) the preliminary prospectus supplement dated June 3, 2013 relating to the Series A Equity Units Offering and (ii) the preliminary prospectus supplement dated June 3, 2013 relating to the Series B Equity Units Offering, in each case, including the documents incorporated by reference therein and the related base prospectus dated January 27, 2012, filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended (Registration Statement File No. 333-179213). Terms used but not defined herein, with respect to either Offering, have the meanings ascribed to them in the preliminary prospectus supplement for such Offering.

Company Dominion Resources, Inc.

Company Stock Ticker New York Stock Exchange D

Trade Date June 4, 2013

Closing Price on June 3, 2013 \$55.55 per share

Settlement Date June 7, 2013

Registration Format SEC Registered

Series A Equity Units Offering

Title of Securities

2013 Series A Equity Units (each being referred to in this Series A Equity Units Offering section as an Equity Unit) that will each have a stated amount of \$50 and will initially be in the form of a 2013 Series A Corporate Unit (each being referred to in this Series A Equity Units Offering section as a Corporate Unit) consisting of a purchase contract issued by the Company and, initially, a 1/20 undivided beneficial ownership interest in \$1,000 principal amount of 2013 Series A 1.07% Remarketable Subordinated Notes due 2021 to be issued by the Company (each being referred to in this Series A Equity Units Offering section as an RSN)

Number of Equity Units Offered 10,000,000 (or 11,000,000 if the underwriters exercise their option to purchase up to 1,000,000 additional Corporate Units in full, solely for the purpose of covering over-allotments) \$500,000,000 (or \$550,000,000 if the underwriters exercise their Aggregate Offering Amount option to purchase up to 1,000,000 additional Corporate Units in full, solely for the purpose of covering over-allotments) \$50.00 Stated Amount per Equity Unit Public Offering Price; Underwriting Discounts and Commissions The Corporate Units are being offered to the underwriters at a price of \$48.50 per Corporate Unit (a discount of \$1.50 from the stated amount per Corporate Unit or \$15,000,000 total discount from the total stated amount). The Corporate Units are being offered to the public at a price of \$49 per Corporate Unit, for a total of \$490,000,000. Dominion s proceeds from the Series A Equity Units Offering (after underwriting discounts of \$0.50 per Corporate Unit from the public offering price (totaling \$5,000,000) and before expenses) will equal \$48.50 per Corporate Unit, for a total of \$485,000,000. Interest Rate on the RSNs 1.07% per year subject to the Company s right to defer interest payments, as described in the relevant preliminary prospectus supplement and subject to modification in connection with a successful remarketing Deferred Interest on the RSNs Deferred interest on the RSNs will bear interest at the interest rate applicable to the RSNs, compounded on each interest payment date to, but excluding, the interest payment date on which such deferred interest is paid 5.055% per year or \$2.5275 per year on the Stated Amount per Contract Adjustment Payment Rate Equity Unit subject to the Company s right to defer contract adjustment payments, as described in the relevant preliminary prospectus supplement Deferred contract adjustment payments will accrue additional Deferred Contract Adjustment Payments contract adjustment payments at the rate equal to 6.125% per annum compounded on each contract adjustment payment date to, but excluding, the contract adjustment payment date on which such deferred contract adjustment payments are paid Total Distribution Rate on the Corporate Units 6.125% per annum Reference Price \$55.55 (subject to adjustment, as described in the relevant preliminary prospectus supplement) Threshold Appreciation Price \$65.2742 (subject to adjustment, as described in the relevant preliminary prospectus supplement), which represents appreciation of approximately 17.5% over the Reference Price Minimum Settlement Rate 0.7660 shares of the Company s common stock (subject to adjustment, as described in the relevant preliminary prospectus supplement), which is approximately equal to the \$50.00 Stated Amount per Equity Unit, divided by the Threshold Appreciation Price

Maximum Settlement Rate 0.9001 shares of the Company s common stock (subject to

adjustment, as described in the relevant preliminary prospectus supplement), which is approximately equal to the \$50.00 Stated Amount per Equity Unit, divided by the Reference Price

Purchase Contract Settlement Date April 1, 2016 (or if such day is not a business day, the following

business day)

RSN Maturity Date April 1, 2021

Estimated Net Proceeds to the Company from the Series A Equity Units

Offering

The net proceeds from the sale of Equity Units in the Series A Equity Units Offering will be \$485 million (or \$533.5 million if the underwriters exercise their over-allotment option in full), after deducting the underwriting discounts and commissions but before deducting other offering expenses

Joint Book-Running Managers Goldman, Sachs & Co.

J.P. Morgan Securities LLC

Merrill Lynch, Pierce, Fenner & Smith

Incorporated

UBS Securities LLC

Listing The Company intends to apply to list the Corporate Units on the

New York Stock Exchange and expects trading to commence within 30 days of the date of initial issuance of the Corporate Units

under the symbol DCUA.

CUSIP for the Corporate Units 25746U 703

ISIN for the Corporate Units US25746U7037

CUSIP for the Treasury Units 25746U 802

ISIN for the Treasury Units US25746U8027

CUSIP for the RSNs 25746U BT5

ISIN for the RSNs US25746UBT51

Allocation of the Purchase Price At the time of issuance, the fair market value of the applicable

ownership interest in the RSNs will be \$49 (or 100% of the issue price of a Corporate Unit) and the fair market value of each purchase contract will be \$0 (or 0% of the issue price of a

Corporate Unit).

Early Settlement Subject to certain conditions described under Description of the Purchase Contracts Early Settlement in the relevant preliminary

prospectus supplement, a holder of Corporate Units or 2013 Series A Treasury Units (each being referred to in this Series A Equity Units Offering section as a Treasury Unit) may settle the related purchase contracts at any time prior to 4:00 p.m., New York City time, on the second business day immediately preceding the

time, on the second business day immediately preceding the Purchase Contract Settlement Date, other than during a blackout

period (as described in the relevant preliminary prospectus supplement) in the case of Corporate Units. An early settlement may be made only in integral multiples of 20

Early Settlement Upon a Fundamental Change

Corporate Units or 20 Treasury Units; however, if the Treasury portfolio has replaced the RSNs as a component of the Corporate Units following a successful optional remarketing, holders of Corporate Units may settle early only in integral multiples of 800,000 Corporate Units. If a purchase contract is settled early, the number of shares of common stock to be issued per purchase contract will be equal to the Minimum Settlement Rate (subject to adjustment, as described in the relevant preliminary prospectus supplement).

Subject to certain conditions described under Description of the Purchase Contracts Early Settlement Upon a Fundamental Change, following a fundamental change (as defined in the relevant preliminary prospectus supplement) that occurs prior to the 20th business day preceding the Purchase Contract Settlement Date, each holder of a purchase contract will have the right to accelerate and settle the purchase contract early on the fundamental change early settlement date (as defined in the relevant preliminary prospectus supplement) at the settlement rate determined as if the applicable market value equaled the stock price (as defined in the relevant preliminary prospectus supplement), plus an additional make-whole amount of shares (such additional make-whole amount of shares being hereafter referred to as the make-whole shares). This right is referred to as the fundamental change early settlement right.

The number of make-whole shares per purchase contract applicable to a fundamental change early settlement will be determined by reference to the table below, based on the date on which the fundamental change occurs or becomes effective (the effective date) and the stock price (as defined in the relevant preliminary prospectus supplement) for the fundamental change:

Stock Price on Effective Date

| Effective | | | | | | | | | | | | | | |
|-----------|---------|---------|---------|---------|---------|---------|---------|----------|----------|----------|----------|----------|----------|----------|
| Date | \$15.00 | \$30.00 | \$45.00 | \$55.55 | \$60.00 | \$65.27 | \$80.00 | \$100.00 | \$130.00 | \$150.00 | \$175.00 | \$200.00 | \$250.00 | \$300.00 |
| June 7. | φ15.00 | φ30.00 | φ45.00 | φυυ.υυ | φυυ.υυ | φυ3.27 | φου.υυ | φ100.00 | φ130.00 | φ130.00 | φ1/5.00 | φ200.00 | φ250.00 | φ300.00 |
| 2013 | 0.1205 | 0.0596 | 0.0252 | 0.0000 | 0.0433 | 0.0940 | 0.0594 | 0.0383 | 0.0294 | 0.0272 | 0.0254 | 0.0241 | 0.0223 | 0.0211 |
| April 1, | | | | | | | | | | | | | | |
| 2014 | 0.1061 | 0.0529 | 0.0240 | 0.0000 | 0.0378 | 0.0856 | 0.0477 | 0.0293 | 0.0232 | 0.0215 | 0.0200 | 0.0188 | 0.0172 | 0.0162 |
| April 1, | | | | | | | | | | | | | | |
| 2015 | 0.0535 | 0.0267 | 0.0128 | 0.0000 | 0.0210 | 0.0625 | 0.0228 | 0.0138 | 0.0117 | 0.0109 | 0.0101 | 0.0096 | 0.0088 | 0.0082 |
| April 1, | | | | | | | | | | | | | | |
| 2016 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |

The stock prices set forth in the second row of the table above (i.e., the column headers) will be adjusted upon the occurrence of certain events requiring anti-dilution adjustments to the fixed settlement rates in a manner inversely proportional to the adjustments to the fixed settlement rates, as described in the relevant preliminary prospectus supplement.

The exact stock price and effective date applicable to a fundamental change may not be set forth on the table, in which case:

if the stock price is between two stock prices on the table or the effective date is between two effective dates on the table, the amount of make-whole shares will be determined

by straight line interpolation between the make-whole share amounts set forth for the higher and lower stock prices and the earlier and later two effective dates based on a 365-day year, as applicable;

if the stock price is in excess of \$300.00 per share (subject to adjustment in the same manner as the stock prices set forth in the second row of the table, as described above), then the make-whole share amount will be zero; and

if the stock price is less than \$15.00 per share (subject to adjustment in the same manner as the stock prices set forth in the second row of the table, as described above) (the minimum stock price), then the make-whole share amount will be determined as if the stock price equaled the minimum stock price, using straight line interpolation, as described above in the first bullet, if the effective date is between two effective dates on the table.

Unless the Treasury portfolio has replaced the RSNs as a component of the Corporate Units as a result of a successful optional remarketing, holders of Corporate Units may exercise the fundamental change early settlement right only in integral multiples of 20 Corporate Units. If the Treasury portfolio has replaced the RSNs as a component of Corporate Units, holders of the Corporate Units may exercise the fundamental change early settlement right only in integral multiples of 800,000 Corporate Units. A holder of Treasury Units may exercise the fundamental change early settlement right only in integral multiples of 20 Treasury Units.

Series B Equity Units Offering

Title of Securities 2013 Series B Equity Units (each being referred to in this Series B

Equity Units Offering section as an Equity Unit) that will each have a stated amount of \$50 and will initially be in the form of a 2013 Series B Corporate Unit (each being referred to in this Series B Equity Units Offering section as a Corporate Unit) consisting of a purchase contract issued by the Company and, initially, a 1/20 undivided beneficial ownership interest in \$1,000 principal amount of 2013 Series B 1.18% Remarketable Subordinated Notes due 2019 to be issued by the Company (each being referred to in this Series B Equity Units Offering section as an RSN)

10,000,000 (or 11,000,000 if the underwriters exercise their option Number of Equity Units Offered to purchase up to 1,000,000 additional Corporate Units in full, solely for the purpose of covering over-allotments)

> \$500,000,000 (or \$550,000,000 if the underwriters exercise their option to purchase up to 1,000,000 additional Corporate Units in full, solely for the purpose of covering over-allotments)

\$50.00

Stated Amount per Equity Unit

Aggregate Offering Amount

Public Offering Price; Underwriting Discounts and Commissions The Corporate Units are being offered to the underwriters at a price of \$48.50 per Corporate Unit (a discount of \$1.50 from the stated amount per Corporate Unit or \$15,000,000 total discount from the total stated amount). The Corporate Units are being offered to the public at a price of \$49 per Corporate Unit, for a total of \$490,000,000. Dominion s proceeds from the Series B Equity Units Offering (after underwriting discounts of \$0.50 per Corporate Unit from the public offering price (totaling \$5,000,000) and before expenses) will equal \$48.50 per Corporate Unit, for a total of \$485,000,000. Interest Rate on the RSNs 1.18% per year subject to the Company s right to defer interest payments, as described in the relevant preliminary prospectus supplement and subject to modification in connection with a successful remarketing Deferred Interest on the RSNs Deferred interest on the RSNs will bear interest at the interest rate applicable to the RSNs, compounded on each interest payment date to, but excluding, the interest payment date on which such deferred interest is paid Contract Adjustment Payment Rate 4.82% per year or \$2.41 per year on the Stated Amount per Equity Unit subject to the Company s right to defer contract adjustment payments, as described in the relevant preliminary prospectus supplement Deferred contract adjustment payments will accrue additional **Deferred Contract Adjustment Payments** contract adjustment payments at the rate equal to 6.00% per annum compounded on each contract adjustment payment date to, but excluding, the contract adjustment payment date on which such deferred contract adjustment payments are paid Total Distribution Rate on the Corporate Units 6.00% per annum Reference Price \$55.55 (subject to adjustment, as described in the relevant preliminary prospectus supplement) Threshold Appreciation Price \$65.2742 (subject to adjustment, as described in the relevant preliminary prospectus supplement), which represents appreciation of approximately 17.5% over the Reference Price 0.7660 shares of the Company s common stock (subject to Minimum Settlement Rate adjustment, as described in the relevant preliminary prospectus supplement), which is approximately equal to the \$50.00 Stated Amount per Equity Unit, divided by the Threshold Appreciation Price Maximum Settlement Rate 0.9001 shares of the Company s common stock (subject to adjustment, as described in the relevant preliminary prospectus supplement), which is approximately equal to the \$50.00 Stated Amount per Equity Unit, divided by the Reference Price Purchase Contract Settlement Date July 1, 2016 (or if such day is not a business day, the following business day) **RSN Maturity Date** July 1, 2019

Estimated Net Proceeds to the Company from the Series B Equity Units Offering

The net proceeds from the sale of Equity Units in the Series B Equity Units Offering will be \$485 million (or \$533.5 million if the underwriters exercise their over-allotment option in full), after deducting the underwriting discounts and commissions but before deducting other offering expenses

Joint Book-Running Managers

Goldman, Sachs & Co.

J.P. Morgan Securities LLC

Merrill Lynch, Pierce, Fenner & Smith

Incorporated

UBS Securities LLC

Listing

The Company intends to apply to list the Corporate Units on the New York Stock Exchange and expects trading to commence within 30 days of the date of initial issuance of the Corporate Units under the symbol DCUB.

CUSIP for the Corporate Units

CUSIP for the Treasury Units

ISIN for the Corporate Units

25746U 877

25746U 885

ISIN for the Treasury Units

US25746U8779

US25746U8852

CUSIP for the RSNs

25746U BU2

ISIN for the RSNs

US25746UBU25

Allocation of the Purchase Price

At the time of issuance, the fair market value of the applicable ownership interest in the RSNs will be \$49 (or 100% of the issue price of a Corporate Unit) and the fair market value of each purchase contract will be \$0 (or 0% of the issue price of a Corporate Unit).

Early Settlement

Subject to certain conditions described under Description of the Purchase Contracts Early Settlement in the relevant preliminary prospectus supplement, a holder of Corporate Units or 2013 Series B Treasury Units (each being referred to in this Series B Equity Units Offering section as a Treasury Unit) may settle the related purchase contracts at any time prior to 4:00 p.m., New York City time, on the second business day immediately preceding the Purchase Contract Settlement Date, other than during a blackout period (as described in the relevant preliminary prospectus supplement) in the case of Corporate Units. An early settlement may be made only in integral multiples of 20 Corporate Units or 20 Treasury Units; however, if the Treasury portfolio has replaced the RSNs as a component of the Corporate Units following a successful optional remarketing, holders of Corporate Units may settle early only in integral multiples of 400,000 Corporate Units. If a purchase contract is settled early, the number of shares of common stock to be issued per purchase contract will be equal to the Minimum Settlement Rate (subject to adjustment, as described in the relevant

preliminary prospectus supplement).

Early Settlement Upon a Fundamental Change

Subject to certain conditions described under Description of the Purchase Contracts Early Settlement Upon a

7

Fundamental Change, following a fundamental change (as defined in the relevant preliminary prospectus supplement) that occurs prior to the 20th business day preceding the Purchase Contract Settlement Date, each holder of a purchase contract will have the right to accelerate and settle the purchase contract early on the fundamental change early settlement date (as defined in the relevant preliminary prospectus supplement) at the settlement rate determined as if the applicable market value equaled the stock price (as defined in the relevant preliminary prospectus supplement), plus an additional make-whole amount of shares (such additional make-whole shares). This right is referred to as the fundamental change early settlement right.

The number of make-whole shares per purchase contract applicable to a fundamental change early settlement will be determined by reference to the table below, based on the date on which the fundamental change occurs or becomes effective (the effective date) and the stock price (as defined in the relevant preliminary prospectus supplement) for the fundamental change:

| Stock | Price | ωn | Effective | Data |
|-------|-------|----|-----------|------|
| | | | | |

| Effective | | | | | | | | | | | | | | |
|-----------|---------|---------|---------|---------|---------|---------|---------|----------|----------|----------|----------|----------|----------|----------|
| Date | \$15.00 | \$30.00 | \$45.00 | \$55.55 | \$60.00 | \$65.27 | \$80.00 | \$100.00 | \$130.00 | \$150.00 | \$175.00 | \$200.00 | \$250.00 | \$300.00 |
| June 7, | | | | | | | | | | | | | | |
| 2013 | 0.1207 | 0.0596 | 0.0246 | 0.0000 | 0.0442 | 0.0955 | 0.0619 | 0.0404 | 0.0308 | 0.0285 | 0.0266 | 0.0253 | 0.0235 | 0.0223 |
| July 1, | | | | | | | | | | | | | | |
| 2014 | 0.0979 | 0.0488 | 0.0213 | 0.0000 | 0.0358 | 0.0838 | 0.0462 | 0.0281 | 0.0223 | 0.0207 | 0.0193 | 0.0182 | 0.0167 | 0.0158 |
| July 1, | | | | | | | | | | | | | | |
| 2015 | 0.0494 | 0.0247 | 0.0115 | 0.0000 | 0.0200 | 0.0616 | 0.0220 | 0.0132 | 0.0113 | 0.0105 | 0.0098 | 0.0093 | 0.0085 | 0.0080 |
| July 1, | | | | | | | | | | | | | | |
| 2016 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |

The stock prices set forth in the second row of the table above (i.e., the column headers) will be adjusted upon the occurrence of certain events requiring anti-dilution adjustments to the fixed settlement rates in a manner inversely proportional to the adjustments to the fixed settlement rates, as described in the relevant preliminary prospectus supplement.

The exact stock price and effective date applicable to a fundamental change may not be set forth on the table, in which case:

if the stock price is between two stock prices on the table or the effective date is between two effective dates on the table, the amount of make-whole shares will be determined by straight line interpolation between the make-whole share amounts set forth for the higher and lower stock prices and the earlier and later two effective dates based on a 365-day year, as applicable;

if the stock price is in excess of \$300.00 per share (subject to adjustment in the same manner as the stock prices set forth in the

second row of the table, as described above), then the make-whole share amount will be zero; and

if the stock price is less than \$15.00 per share (subject to adjustment in the same manner as the stock prices set forth in the second row of the table, as described above) (the

8

minimum stock price), then the make-whole share amount will be determined as if the stock price equaled the minimum stock price, using straight line interpolation, as described above in the first bullet, if the effective date is between two effective dates on the table.

Unless the Treasury portfolio has replaced the RSNs as a component of the Corporate Units as a result of a successful optional remarketing, holders of Corporate Units may exercise the fundamental change early settlement right only in integral multiples of 20 Corporate Units. If the Treasury portfolio has replaced the RSNs as a component of Corporate Units, holders of the Corporate Units may exercise the fundamental change early settlement right only in integral multiples of 400,000 Corporate Units. A holder of Treasury Units may exercise the fundamental change early settlement right only in integral multiples of 20 Treasury Units.

The issuer has filed a registration statement (including a prospectus), as amended, with the SEC for the offering to which this communication relates (File No. 333-179213). Before you invest, you should read the prospectus in that registration statement and other documents the issuer has filed with the SEC for more complete information about the issuer and the Offerings. You may get these documents for free by visiting EDGAR on the SEC Website at www.sec.gov. Alternatively, the issuer, any underwriter or any dealer participating in the relevant Offering will arrange to send you the base prospectus and the relevant preliminary prospectus supplement if you request them by calling BofA Merrill Lynch at 1-866-500-5408; or Goldman, Sachs & Co. at 1-866-471-2526; or J.P. Morgan Securities LLC at 1-866-803-9204; or UBS Investment Bank at 1-877-827-6444.

This communication should be read in conjunction with the relevant preliminary prospectus supplement and the accompanying base prospectus. The information in this communication supersedes the information in the relevant preliminary prospectus supplement and the accompanying base prospectus to the extent inconsistent with the information in such preliminary prospectus supplement and the accompanying base prospectus.

ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW ARE NOT APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA BLOOMBERG OR ANOTHER EMAIL SYSTEM.